ASCO 2021 Annual Meeting
The results were presented during the 2021 ASCO Annual Meeting.
Ph-like ALL is a high-risk subgroup with increased prevalence in younger adults.
A retrospective study assessed how advanced care planning affected end-of-life outcomes in patients who underwent allo-HCT.
A study presented during ASCO 2021 reviewed a program to streamline discussions surrounding fertility preservation options.
The results were presented during the 2021 ASCO Annual Meeting.
Data were collected on 541 patients with incurable solid tumor or lymphoma considering any line of cancer treatment.
Satisfaction with telehealth is on the rise. However, differences persist by demographic.
The lives of patients who undergo hematopoietic stem cell transplantation (HSCT) change in several ways.
Final analysis included 138 patients who underwent lung metastasectomy.
Acute panmyelosis with myelofibrosis (APMF) is a rare disease with limited population-based data.
Final analysis included 104,135 matched pairs of patients with and without cancer-related diarrhea.
The study included patients diagnosed with cancer and PCR-confirmed COVID-19.
The researchers queried PubMed, EMBASE, ASCO, and San Antonio Breast Cancer Symposium meeting abstracts.
A study presented during ASCO 2021 assessed the prevalence of germline testing at a breast cancer survivorship clinic.
PROs are outcomes directly reported by the patient without interpretation from a clinician.
For patients with myelofibrosis, the only curative treatment option is allogenic hematopoietic cell transplant (allo-HCT).
Researchers identified patients with Philadelphia-negative MPN and compared patients with versus without sepsis.
It is often challenging for patients with advanced cancer to make decisions surrounding end-of-life (EOL) care.
630 Madison Ave.
Manalapan, NJ 07726
© 2024 Mashup Media, LLC. All rights reserved.